Vk5211 and vk2809 have a 2 + billion dollar potential for both, they will both be Major blockbuster drugs, and we have a couple other drugs in pipeline as well. As far a news goes we should see some more P2 data on Vk5211 in the coming months. Not sure what the next news will be but it could be a Partnership or a Buyout but I think that will come after 2809 results.
The Main driver for VKTX right now is the Valuation ...it hugely undervalued compared to its Peer MDGL that has a similar drug that just completed P2 as VK2809 that will be in early Q3, and if you look at past data 2809 has better data and is a more effective lipid drug. Based on Market Cap VKTX should be trading at 30.00 to MDGL's valuation.
News 
Market Data 
Discover 
